Gaby Bourbara's lobbying: the registrations they file and every meeting they've reported since November 2021.
← LobbyingRegistrant (responsible officer)
President
For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.
Canada's Drug Agency policies and processes as it relates to reimbursement recommendation decision-making process and framework
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Federally-funded Public Drug Plans, including the Non Insured Health Benefits program, with respect to reimbursement for drug products for beneficiaries.
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Establish accountability with Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance, as well as Regulations, policies and programs related to the review and reimbursement processes
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
Scientific Research and Experimental Development (SR&ED) Tax Incentive Program regarding eligible expenditures. Discussions on policies such as "patent box" and Investment Tax Credits.
Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes
Annual federal Budgets and Budget updates relating to the biopharmaceutical industry.
Engagement with the Government regarding the Strategic Response Fund (SRF) (previously known as SIF) and investment in Canada
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry, as well as free trade agreements as they relate to the biopharmaceutical industry
Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.
Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance.
Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.
Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance.
Patented Medicine Prices Review Board (PMPRB) regarding development and implementation of guidelines to operationalize regulatory amendments.
Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.
Engage with Canadian government officials to discuss and provide input on Canada’s countermeasures and policies in response to foreign tariffs affecting the pharmaceutical industry
Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance.
Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.
Patented Medicine Prices Review Board (PMPRB) regarding development and implementation of guidelines to operationalize regulatory amendments.
Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance.
Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.
Patented Medicine Prices Review Board (PMPRB) regarding development and implementation of guidelines to operationalize regulatory amendments.
Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.
Regulations, policies and programs related to the review and reimbursement processes of Health Canada, Canada’s Drug Agency and the pan-Canadian Pharmaceutical Alliance.
Patent Act, Patented Medicines (Notice of Compliance) Regulations, Data Protection Regulation, Certificates of Supplementary Protection and related policies regarding the regulation of intellectual property for biopharmaceutical products, and maintaining international competitiveness.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.